Ibere Pharmaceuticals
Status: Liquidated
U=S+W/2
W=S@11.5
IPO Proceeds, $M | $138.00M |
---|---|
IPO Date | Feb 26, 2021 |
CEO | Osagie Imasogie |
Left Lead | Raymond James |
IPO Cash in Trust | 100.0% |
SPAC Tenor | 24 months |
IPO Sector | Healthcare |
IPO Geography | Global |
Target Company | N/A |
Deal Announced | N/A |
Deal Size, $M | TBD |
Deal Sector | TBD |
Deal Geography | TBD |
SEC Filings | www.sec.gov |
Approval Vote | TBD |
Amendment Vote | TBD |
Closing Date | Mar 2, 2023 |
IBER
IBER.U
IBER/W
Price | |
---|---|
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Ibere Pharmaceuticals:
- Structure and cap table
- 7 directors & officers
- 7 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Osagie Imasogie | 59 | Chairman, Chief Executive Officer and Director |
Lisa Gray | 56 | Chief Financial Officer, Executive Vice President and Director |
Zoltan Kerekes | 55 | Chief Operating Officer, Executive Vice President and Director |
Louis J. Vollmer | 64 | Director |
Elaine V. Jones | 66 | Director |
Henrietta Ukwu | 61 | Director |
Calvin B. Johnson | 54 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Raymond James | BR | 12,000,000 | units |
12,000,000 | units | ||
Up-Front UW fee | 2.00 | % | |
Deferred UW fee | 3.50 | % |
Sign in to view more advisor data.
Filings
Sign in to view 7 filings.